Antibody Partnering Terms and Agreements -





The Antibody Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides a detailed understanding and analysis of how and why companies enter antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:  

  • Antibodies
  • Antibody-drug conjugates
  • Monoclonal antibodies
    • Murine mAb
    • Chimeric mAb
    • Humanized mAb
    • Human mAb
    • Polyclonal Antibodies
     

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not. 

                                

This report contains over 900 links to online copies of actual antibody deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in antibody dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

                    

Chapter 3 provides a review of the leading antibody deals since 2009. Deals are listed by headline value, signed by big pharma, most active big pharma and big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with antibodies deals announced along with a brief summary followed by a comprehensive listing of antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive and detailed review of antibody partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus and specific technology type. Each deal title links via Weblink to an online version of the deal record and the contract document, providing easy access to each contract document on demand.

 

Chapter 7 provides a comprehensive and detailed review of antibody partnering deals signed and announced since January 2009. The chapter is organized by specific antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in antibody partnering and dealmaking since 2009.

 

In addition, a comprehensive appendix is provided organized by antibody partnering company A-Z ,deal type, stage of development type and therapy type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

                                                  

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of antibody technologies and products.

                                                    

Report scope

                          

Antibody Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to antibody trends and structure of deals entered into by leading companies worldwide.

                                              

Antibody Partnering Terms and Agreements includes:

                                                       

  • Trends in antibody dealmaking in the biopharma industry since 2009
  • Analysis of antibody deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life antibody deals
  • Access to over 900 antibody deal records and contract documents where available
  • The leading antibody deals by value since 2009
  • Most active antibody dealmakers since 2009
  • The leading antibody partnering resources

  

In Antibody Partnering Terms and Agreements, the available contracts are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

 The Antibody Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 900 antibody deals. Analyzing actual contract agreements allows assessment of the following:

                                 

  • What are the precise antibody rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Executive Summary 

Chapter 1 – Introduction 

Chapter 2 – Trends in antibody dealmaking 

2.1. Introduction

2.2. Antibody partnering over the years

2.3. Big pharma antibody dealmaking activity

2.4 Big Biotech antibody dealmaking activity

2.5. Top 10 active antibody dealmakers

2.6. Antibody partnering by deal type

2.7. Antibody partnering by disease type

2.8. Antibody partnering by stage of development

2.9. Partnering by antibody type

2.10. Average deal terms for antibody partnering

2.10.1 Antibody partnering by headline values

2.10.2 Antibody partnering by upfront payments

2.10.3 Antibody partnering by milestone payments

2.10.4 Antibody partnering by royalty rates

2.11. The anatomy of antibody partnering

2.11. The anatomy of an antibody deal

2.11.a. Case study 1: ADMA Biologics- Biotest: December 31 2012

2.11.b. Case study 2: Amgen- AstraZeneca: April 2, 2012

 

Chapter 3 – Leading antibody deals 

 

3.1. Introduction

3.2. Top antibody deals by value

 

Chapter 4 – Big pharma antibody deals 

 

4.1. Introduction

4.2. How to use big pharma antibody partnering deals

4.3. Big pharma antibody partnering company profiles

  

Chapter 5 – Big Biotech antibody deals 

 

5.1. Introduction

5.2. How to use big biotech partnering deals

5.3. Big biotech antibody partnering company profiles

  

Chapter 6 – Antibody dealmaking directory with contract documents 

 

6.1. Introduction

6.2. Antibody dealmaking with contract documents by company A-Z

6.3. Antibody dealmaking with contract documents by stage of development

6.4. Antibody dealmaking with contract documents by deal type

6.5. Antibody dealmaking with contract documents by therapy area

 

Chapter 7- Antibody dealmaking by antibody technology type 

 

7.1. Introduction

7.2. Deals by antibody type

 Note: For full list of antibody deals announced - see appendices 1-4

 

Chapter 8 – Antibody partnering resource center 

 

8.1. Online antibody partnering

8.2. Antibody partnering events

8.3. Further reading on antibody dealmaking

About Wildwood Ventures

Current Partnering

Current Agreements

Recent report titles from CurrentPartnering

Order Form – Upgrades to subscription access products

Order Form – Reports

 

Table of figures 

 

Figure 1: Therapeutic antibody definitions

Figure 2: Antibody partnering since 2009

Figure 3: Big pharma – top 50 – antibody deals 2009 to 2014

Figure 4: Big pharma antibody deal frequency – 2009 to 2014

Figure 5: Big biotech – top 50 – antibody deals 2009 to 2014

Figure 6: Big biotech antibody deal frequency – 2009 to 2014

Figure 7: Top 10 antibody dealmakers – 2009 to 2014

Figure 8: Antibody partnering by deal type since 2009

Figure 9: Antibody partnering by disease type since 2009

Figure 10: Antibody partnering by oncology target since 2009

Figure 11: Antibody partnering by stage of development since 2009

Figure 12: Antibody partnering by therapeutic antibody type since 2009

Figure 13: Antibody deals with a headline value by year- 2014

Figure 14: Antibody deals with a headline value by year- 2013

Figure 15: Antibody deals with a headline value by year- 2012

Figure 16: Antibody deals with a headline value by year- 2011

Figure 17: Antibody deals with a headline value by year- 2010

Figure 18: Antibody deals with a headline value by year- 2009

Figure 19: Antibody deal by headline value distribution, US$million – 2014

Figure 20: Antibody deal by headline value distribution, US$million – 2013

Figure 21: Antibody deal by headline value distribution, US$million – 2012

Figure 22: Antibody deal by headline value distribution, US$million – 2011

Figure 23: Antibody deal by headline value distribution, US$million – 2010

Figure 24: Antibody deal by headline value distribution, US$million – 2009

Figure 25: Summary median headline value by year, 2009-2014

Figure 26: Antibody deals with an upfront value by year- 2014

Figure 27: Antibody deals with an upfront value by year- 2013

Figure 28: Antibody deals with an upfront value by year- 2012

Figure 29: Antibody deals with an upfront value by year- 2011

Figure 30: Antibody deals with an upfront value by year- 2010

Figure 31: Antibody deals with an upfront value by year- 2009

Figure 32: Antibody deal by upfront value distribution, US$million – 2014

Figure 33: Antibody deal by upfront value distribution, US$million – 2013

Figure 34: Antibody deal by upfront value distribution, US$million – 2012

Figure 35: Antibody deal by upfront value distribution, US$million – 2011

Figure 36: Antibody deal by upfront value distribution, US$million – 2010

Figure 37: Antibody deal by upfront value distribution, US$million – 2009

Figure 38: Summary median upfront value by year, 2009-2014

Figure 39: Antibody deals with a milestone value by year- 2014

Figure 40: Antibody deals with a milestone value by year- 2013

Figure 41: Antibody deals with a milestone value by year- 2012

Figure 42: Antibody deals with a milestone value by year- 2011

Figure 43: Antibody deals with a milestone value by year- 2010

Figure 44: Antibody deals with a milestone value by year- 2009

Figure 45: Antibody deal by milestone value distribution, US$million – 2014

Figure 46: Antibody deal by milestone value distribution, US$million – 2013

Figure 47: Antibody deal by milestone value distribution, US$million – 2012

Figure 48: Antibody deal by milestone value distribution, US$million – 2011

Figure 49: Antibody deal by milestone value distribution, US$million – 2010

Figure 50: Antibody deal by milestone value distribution, US$million – 2009

Figure 51: Antibody deals with a royalty rate by year- 2014

Figure 52: Antibody deals with a royalty rate value by year- 2013

Figure 53: Antibody deals with a royalty rate value by year- 2012

Figure 54: Antibody deals with a royalty rate value by year- 2011

Figure 55: Antibody deals with a royalty rate value by year- 2010

Figure 56: Antibody deals with a royalty rate value by year- 2009

Figure 57: Antibody deal by royalty rate value distribution, US$million – 2014

Figure 58: Antibody deal by royalty rate value distribution, US$million – 2013

Figure 59: Antibody deal by royalty rate value distribution, US$million – 2012

Figure 60: Antibody deal by royalty rate value distribution, US$million – 2011

Figure 61: Antibody deal by royalty rate value distribution, US$million – 2010

Figure 62: Antibody deal by royalty rate value distribution, US$million – 2009

Figure 63: Summary median royalty rate by year, 2009-2014

Figure 64: Components of the typical antibody deal structure

Figure 65: Top antibody deals by value since 2009

Figure 66: Online partnering resources

Figure 67: Forthcoming partnering events